Triple-Negative Breast Cancer Database

1. Zhao, C., et al., Genome-wide profiling of AP-1 regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res, 2014. PMID:24830720
2. Zhang, C., et al., Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. Int J Oncol, 2014. 44(6): p. 2025-33. PMID:24676531
3. Zhang, B., et al., Protein interacting with C alpha kinase 1 (PICK1) is involved in promoting tumor growth and correlates with poor prognosis of human breast cancer. Cancer Sci, 2010. 101(6): p. 1536-42. PMID:20384629
4. Yu, X., et al., Diversin is overexpressed in breast cancer and accelerates cell proliferation and invasion. PLoS One, 2014. 9(5): p. e98591. PMID:24858714
5. Yang, L., et al., FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene, 2011. 30(43): p. 4437-46. PMID:21532620
6. Yang, L., et al., Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer, 2014. 14: p. 124. PMID:24564888
7. Yamamoto, M., et al., Epigenetic alteration of the NF-kappaB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer. Cancer Sci, 2010. 101(11): p. 2391-7. PMID:20735436
8. Xia, H., et al., Kruppel-like factor 5 transcription factor promotes microsomal prostaglandin E2 synthase 1 gene transcription in breast cancer. J Biol Chem, 2013. 288(37): p. 26731-40. PMID:23913682
9. Wu, M., L. Liu, and C. Chan, Identification of novel targets for breast cancer by exploring gene switches on a genome scale. BMC Genomics, 2011. 12: p. 547. PMID:22053771
10. Wong, T.S., et al., High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res, 2002. 8(2): p. 433-7. PMID:11839660
11. Wiegmans, A.P., et al., Rad51 supports triple negative breast cancer metastasis. Oncotarget, 2014. 5(10): p. 3261-72. PMID:24811120
12. Wen, Y.H., et al., Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res Treat, 2012. 135(1): p. 93-102. PMID:22538771
13. Wang, X., et al., CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst, 2010. 102(19): p. 1496-512. PMID:20852124
14. Wang, W., et al., IRP2 regulates breast tumor growth. Cancer Res, 2014. 74(2): p. 497-507. PMID:24285726
15. Walker, S.R., et al., The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene, 2014. PMID:24662818
16. Tuhkanen, H., et al., Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer. Int J Cancer, 2013. 133(10): p. 2334-40. PMID:23649491
17. Sinha, A., et al., Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J Exp Clin Cancer Res, 2013. 32(1): p. 69. PMID:24330581
18. Salimi, M., H. Mozdarani, and K. Majidzadeh, Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol, 2012. 29(3): p. 1502-9. PMID:21850541
19. Rodriguez-Acebes, S., et al., Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am J Pathol, 2010. 177(4): p. 2034-45. PMID:20724597
20. Ren, Y., et al., microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol Med Rep, 2014. 10(1): p. 315-21. PMID:24821285
21. Pula, B., et al., Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma. Cell Oncol (Dordr), 2013. 36(6): p. 469-83. PMID:24065215
22. Peltonen, H.M., et al., Gamma-secretase components as predictors of breast cancer outcome. PLoS One, 2013. 8(11): p. e79249. PMID:24223915
23. Pelekanou, V., et al., ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids, 2012. 77(10): p. 928-34. PMID:22198466
24. Paul, A., et al., PKClambda/iota signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ, 2014. PMID:24786829
25. Passon, N., et al., Expression of Dicer and Drosha in triple-negative breast cancer. J Clin Pathol, 2012. 65(4): p. 320-6. PMID:22259182
26. Ortiz-Martinez, F., et al., Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol, 2014. 45(3): p. 504-12. PMID:24440093
27. Nozoe, T., et al., Immunohistochemical expression of epidermal growth factor receptor in breast cancer. Breast Cancer, 2011. 18(1): p. 37-41. PMID:20204554
28. Neve, R.M., et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006. 10(6): p. 515-27. PMID:17157791
29. Muniz Lino, M.A., et al., Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9. J Proteomics, 2014. PMID:24768906
30. Montero, J.C., et al., Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014. 33(2): p. 148-56. PMID:23246963
31. Mittendorf, E.A., et al., PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res, 2014. 2(4): p. 361-70. PMID:24764583
32. Miki, Y., et al., Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res, 2006. 66(1): p. 535-42. PMID:16397270
33. Meric, F., et al., Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res, 2002. 8(2): p. 361-7. PMID:11839650
34. McDonald, L., et al., RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Dis Model Mech, 2014. 7(5): p. 525-34. PMID:24626992
35. Mackiewicz, M., et al., Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat, 2011. 130(2): p. 663-79. PMID:21814748
36. Lu, M., et al., Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. Clin Proteomics, 2010. 6(3): p. 93-103. PMID:20930921
37. Liu, X., et al., Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis. BMC Cancer, 2014. 14: p. 57. PMID:24485087
38. Lee, S.T., et al., Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proc Natl Acad Sci U S A, 2013. 110(27): p. 11121-6. PMID:23784775
39. Kulkarni, S., et al., Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One, 2012. 7(8): p. e42895. PMID:22952619
40. Krishnan, K., et al., miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA, 2013. 19(12): p. 1767-80. PMID:24158791
41. Kong, C., et al., NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One, 2011. 6(7): p. e22666. PMID:21829474
42. Kim, Y.J., et al., MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer, 2014. 134(10): p. 2424-36. PMID:24615768
43. Kim, I.J., et al., RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes. Clin Cancer Res, 2002. 8(2): p. 457-63. PMID:11839664
44. Kharman-Biz, A., et al., Expression of activator protein-1 (AP-1) family members in breast cancer. BMC Cancer, 2013. 13: p. 441. PMID:24073962
45. Kerdivel, G., et al., Activation of the MKL1/actin signaling pathway induces hormonal escape in estrogen-responsive breast cancer cell lines. Mol Cell Endocrinol, 2014. 390(1-2): p. 34-44. PMID:24721635
46. Kalashnikova, E.V., et al., ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res, 2010. 70(22): p. 9402-12. PMID:20864510
47. Inagawa, S., et al., Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res, 2002. 8(2): p. 450-6. PMID:11839663
48. Huck, B., et al., Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem, 2014. 289(6): p. 3138-47. PMID:24337579
49. Hu, Z., et al., The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006. 7: p. 96. PMID:16643655
50. Horiuchi, D., et al., MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med, 2012. 209(4): p. 679-96. PMID:22430491
51. Holm, K., et al., Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol, 2012. 6(5): p. 494-506. PMID:22766277
52. Grigoriadis, A., et al., Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics, 2012. 13: p. 619. PMID:23151021
53. Grieb, B.C., X. Chen, and C.M. Eischen, MTBP is Over-expressed in Triple Negative Breast Cancer and Contributes to its Growth and Survival. Mol Cancer Res, 2014. PMID:24866769
54. Geiger, T., et al., Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res, 2012. 72(9): p. 2428-39. PMID:22414580
55. Gartner, S., et al., PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLoS One, 2014. 9(1): p. e84472. PMID:24409301
56. Flatmark, K., et al., Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res, 2002. 8(2): p. 444-9. PMID:11839662
57. Feigin, M.E., et al., G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc Natl Acad Sci U S A, 2014. 111(11): p. 4191-6. PMID:24599592
58. Fagan-Solis, K.D., et al., The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem, 2013. 114(6): p. 1385-94. PMID:23255405
59. Fagan-Solis, K.D., et al., SKP2 Overexpression Is Associated With Increased Serine 10 Phosphorylation of p27 (pSer10p27) in Triple-Negative Breast Cancer. J Cell Physiol, 2014. 229(9): p. 1160-9. PMID:24443386
60. Eswaran, J., et al., Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep, 2012. 2: p. 264. PMID:22355776
61. Esnakula, A.K., et al., Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol, 2014. 67(2): p. 153-60. PMID:23986556
62. Duncan, J.S., et al., Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell, 2012. 149(2): p. 307-21. PMID:22500798
63. Dey, N., et al., Differential activation of Wnt-beta-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One, 2013. 8(10): p. e77425. PMID:24143235
64. Dennison, J.B., et al., Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res, 2013. 19(13): p. 3703-13. PMID:23697991
65. De Summa, S., et al., Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis, 2014. 5: p. e1076. PMID:24556691
66. D'Alfonso, T.M., et al., Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol, 2014. PMID:24904064
67. Cuenca-Lopez, M.D., et al., Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014. 14(1): p. 302. PMID:24779793
68. Cheng, G., et al., HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2. Cancer Res, 2014. 74(3): p. 862-72. PMID:24295734
69. Cheng, D., H. Kong, and Y. Li, TMPRSS4 as a poor prognostic factor for triple-negative breast cancer. Int J Mol Sci, 2013. 14(7): p. 14659-68. PMID:23857060
70. Chan, M.W., et al., Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res, 2002. 8(2): p. 464-70. PMID:11839665
71. Calvano Filho, C.M., et al., Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol, 2014. PMID:24810926
72. Brabender, J., et al., The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res, 2002. 8(2): p. 438-43. PMID:11839661
73. Blanchard, Z., et al., Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One, 2014. 9(4): p. e95663. PMID:24789045
74. Benad, P., et al., The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Lett, 2011. 312(1): p. 101-8. PMID:21899945
75. Ben Gacem, R., et al., Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers. Hum Pathol, 2012. 43(10): p. 1731-8. PMID:22520950
76. Bailey, C.K., et al., High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG. J Biol Chem, 2012. 287(23): p. 19472-86. PMID:22496452
77. Aydogdu, E., et al., MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis, 2012. 33(8): p. 1502-11. PMID:22562546
78. Avery-Kiejda, K.A., et al., Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer, 2014. 14: p. 51. PMID:24479446
79. Avery-Kiejda, K.A., et al., The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer. BMC Cancer, 2014. 14: p. 253. PMID:24725360
80. Albeck, J.G. and J.S. Brugge, Uncovering a tumor suppressor for triple-negative breast cancers. Cell, 2011. 144(5): p. 638-40. PMID:21376226
81. Ahn, S.G., et al., LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat, 2013. 141(1): p. 89-99. PMID:23933800
82. Bernemann, C., et al., Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Mol Cancer, 2014. 13: p. 174. PMID:25033833
83. Ziegler, Y.S., et al., Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment. PLoS One, 2014. 9(7): p. e102341. PMID:25029196
84. Sizemore, G.M., et al., GABA(A) Receptor pi (GABRP) Stimulates Basal-like Breast Cancer Cell Migration Through Activation of Extracellular Regulated Kinase 1/2 (ERK1/2). J Biol Chem, 2014. PMID:25012653
85. Cascione, L., et al., Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One, 2013. 8(2): p. e55910. PMID:23405235
86. Komatsu, M., et al., Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol, 2013. 42(2): p. 478-506. PMID:23254957
87. Lehmann, B.D., et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011. 121(7): p. 2750-67. PMID:21633166

1. Yagata, H., Y. Kajiura, and H. Yamauchi, Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer, 2011. 18(3): p. 165-73. PMID:21290263
2. Yadav, B.S., et al., Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol, 2014. 5(2): p. 125-33. PMID:24829859
3. Xu, H., et al., The omics of triple-negative breast cancers. Clin Chem, 2014. 60(1): p. 122-33. PMID:24298072
4. Whitman, G.J., C.T. Albarracin, and A.M. Gonzalez-Angulo, Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol, 2011. 46(1): p. 26-39. PMID:21134526
5. von Minckwitz, G. and M. Martin, Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol, 2012. 23 Suppl 6: p. vi35-9. PMID:23012300
6. Voduc, D. and T.O. Nielsen, Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Clin Breast Cancer, 2008. 8 Suppl 4: p. S171-8. PMID:19158038
7. Vincent-Salomon, A., [Triple-negative breast cancer]. Rev Prat, 2013. 63(10): p. 1391-2. PMID:24579334
8. Venkitaraman, R., Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther, 2010. 10(2): p. 199-207. PMID:20131996
9. Vasudev, P. and K. Onuma, Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med, 2011. 135(12): p. 1606-10. PMID:22129193
10. Valentin, M.D., et al., Molecular insights on basal-like breast cancer. Breast Cancer Res Treat, 2012. 134(1): p. 21-30. PMID:22234518
11. Turner, N., et al., Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev, 2013. 39(5): p. 541-50. PMID:23321033
12. Toft, D.J. and V.L. Cryns, Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol, 2011. 25(2): p. 199-211. PMID:20861225
13. Teng, Y.H., et al., Therapeutic targets in triple negative breast cancer - where are we now? Recent Pat Anticancer Drug Discov, 2011. 6(2): p. 196-209. PMID:21247402
14. Telli, M.L. and J.M. Ford, Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer, 2010. 10 Suppl 1: p. E16-22. PMID:20587403
15. Tan, A.R. and S.M. Swain, Therapeutic strategies for triple-negative breast cancer. Cancer J, 2008. 14(6): p. 343-51. PMID:19060597
16. Sugie, T., [PARP inhibitors to treat triple negative breast cancer]. Gan To Kagaku Ryoho, 2010. 37(13): p. 2850-5. PMID:21235091
17. Stratford, A.L., et al., Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med, 2010. 12: p. e22. PMID:20653987
18. Stockmans, G., et al., Triple-negative breast cancer. Curr Opin Oncol, 2008. 20(6): p. 614-20. PMID:18841042
19. Stevens, K.N., C.M. Vachon, and F.J. Couch, Genetic susceptibility to triple-negative breast cancer. Cancer Res, 2013. 73(7): p. 2025-30. PMID:23536562
20. Spina, A., et al., Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. Front Biosci (Landmark Ed), 2013. 18: p. 133-44. PMID:23276914
21. Shastry, M. and D.A. Yardley, Updates in the treatment of basal/triple-negative breast cancer. Curr Opin Obstet Gynecol, 2013. 25(1): p. 40-8. PMID:23222093
22. Seal, M.D. and S.K. Chia, What is the difference between triple-negative and basal breast cancers? Cancer J, 2010. 16(1): p. 12-6. PMID:20164685
23. Schneider, B.P., et al., Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res, 2008. 14(24): p. 8010-8. PMID:19088017
24. Schmadeka, R., B.E. Harmon, and M. Singh, Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol, 2014. 141(4): p. 462-77. PMID:24619745
25. Santana-Davila, R. and E.A. Perez, Treatment options for patients with triple-negative breast cancer. J Hematol Oncol, 2010. 3: p. 42. PMID:20979652
26. Rubovszky, G., et al., [Triple-negative breast carcinoma--rewiev of current literature]. Magy Onkol, 2010. 54(4): p. 325-35. PMID:21163763
27. Rodler, E., L. Korde, and J. Gralow, Current treatment options in triple negative breast cancer. Breast Dis, 2010. 32(1-2): p. 99-122. PMID:21778572
28. Reis-Filho, J.S. and A.N. Tutt, Triple negative tumours: a critical review. Histopathology, 2008. 52(1): p. 108-18. PMID:18171422
29. Reeder-Hayes, K.E., L.A. Carey, and W.M. Sikov, Clinical trials in triple negative breast cancer. Breast Dis, 2010. 32(1-2): p. 123-36. PMID:21778571
30. Ray, M. and B.N. Polite, Triple-negative breast cancers: a view from 10,000 feet. Cancer J, 2010. 16(1): p. 17-22. PMID:20164686
31. Rastelli, F., et al., Triple-negative breast cancer: current state of the art. Tumori, 2010. 96(6): p. 875-88. PMID:21388048
32. Rakha, E.A., J.S. Reis-Filho, and I.O. Ellis, Basal-like breast cancer: a critical review. J Clin Oncol, 2008. 26(15): p. 2568-81. PMID:18487574
33. Rakha, E.A. and I.O. Ellis, Triple-negative/basal-like breast cancer: review. Pathology, 2009. 41(1): p. 40-7. PMID:19089739
34. Rakha, E.A. and S. Chan, Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol), 2011. 23(9): p. 587-600. PMID:21524569
35. Prat, A., et al., Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist, 2013. 18(2): p. 123-33. PMID:23404817
36. Podo, F., et al., Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol, 2010. 4(3): p. 209-29. PMID:20537966
37. Plummer, R., Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res, 2011. 13(4): p. 218. PMID:21884642
38. Pierobon, M. and C.L. Frankenfeld, Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat, 2013. 137(1): p. 307-14. PMID:23179600
39. Petrelli, F., et al., Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? Expert Opin Investig Drugs, 2009. 18(10): p. 1467-77. PMID:19737114
40. Peshkin, B.N., M.L. Alabek, and C. Isaacs, BRCA1/2 mutations and triple negative breast cancers. Breast Dis, 2010. 32(1-2): p. 25-33. PMID:21778580
41. Perez, E.A., et al., Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat, 2010. 120(2): p. 285-91. PMID:20094772
42. Peng, Y., Potential prognostic tumor biomarkers in triple-negative breast carcinoma. Beijing Da Xue Xue Bao, 2012. 44(5): p. 666-72. PMID:23073572
43. Penault-Llorca, F. and G. Viale, Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol, 2012. 23 Suppl 6: p. vi19-22. PMID:23012297
44. Pattison, S.T. and B.R. McLaren, Triple negative breast cancer in a male-to-female transsexual. Intern Med J, 2013. 43(2): p. 203-5. PMID:23402485
45. Park, Y., et al., Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Anticancer Agents Med Chem, 2012. 12(6): p. 672-7. PMID:22263793
46. Pal, S.K. and J. Mortimer, Triple-negative breast cancer: novel therapies and new directions. Maturitas, 2009. 63(4): p. 269-74. PMID:19632796
47. Pal, S.K., B.H. Childs, and M. Pegram, Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat, 2011. 125(3): p. 627-36. PMID:21161370
48. O'Toole, S.A., et al., Therapeutic targets in triple negative breast cancer. J Clin Pathol, 2013. 66(6): p. 530-42. PMID:23436929
49. Oakman, C., G. Viale, and A. Di Leo, Management of triple negative breast cancer. Breast, 2010. 19(5): p. 312-21. PMID:20382530
50. Oakman, C., et al., Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur J Cancer, 2011. 47 Suppl 3: p. S370-2. PMID:21944019
51. Nowacka-Zawisza, M. and W.M. Krajewska, [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches]. Postepy Hig Med Dosw (Online), 2013. 67: p. 1090-7. PMID:24379250
52. Nanda, R., "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Semin Oncol, 2011. 38(2): p. 254-62. PMID:21421115
53. Nahleh, Z., Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook. Med Oncol, 2010. 27(2): p. 531-9. PMID:19513864
54. Morrow, M., Personalizing extent of breast cancer surgery according to molecular subtypes. Breast, 2013. 22 Suppl 2: p. S106-9. PMID:24074769
55. Metzger-Filho, O., et al., Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012. 30(15): p. 1879-87. PMID:22454417
56. McNamara, K.M., et al., Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol, 2013. 133: p. 66-76. PMID:22982153
57. McCarthy, N., et al., Triple-negative breast cancer: making the most of a misnomer. Asia Pac J Clin Oncol, 2012. 8(2): p. 145-55. PMID:22524573
58. Mahamodhossen, Y.A., W. Liu, and Z. Rong-Rong, Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol, 2013. 30(3): p. 653. PMID:23824643
59. Ma, C.X., J. Luo, and M.J. Ellis, Molecular profiling of triple negative breast cancer. Breast Dis, 2010. 32(1-2): p. 73-84. PMID:21778575
60. Lv, D., et al., CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell Mol Immunol, 2013. 10(4): p. 303-10. PMID:23376885
61. Liu, N., X. Wang, and X. Sheng, 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis. Curr Opin Obstet Gynecol, 2011. 23(1): p. 19-23. PMID:21150601
62. Linn, S.C. and L.J. Van 't Veer, Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer, 2009. 45 Suppl 1: p. 11-26. PMID:19775601
63. Liedtke, C. and L. Kiesel, Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity. Maturitas, 2012. 73(4): p. 288-94. PMID:23020990
64. Liedtke, C., et al., Genomic profiling in triple-negative breast cancer. Breast Care (Basel), 2013. 8(6): p. 408-13. PMID:24550748
65. Liang, H. and A.R. Tan, Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs, 2010. 13(9): p. 646-56. PMID:20799148
66. Lerma, E., A. Barnadas, and J. Prat, Triple negative breast carcinomas: similarities and differences with basal like carcinomas. Appl Immunohistochem Mol Morphol, 2009. 17(6): p. 483-94. PMID:19620842
67. Lehmann, B.D. and J.A. Pietenpol, Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol, 2014. 232(2): p. 142-50. PMID:24114677
68. Kurbel, S., In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol, 2013. 34(1): p. 1-7. PMID:23208673
69. Koziol, M., M. Puskulluoglu, and A. Zygulska, [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer]. Przegl Lek, 2012. 69(6): p. 265-70. PMID:23094440
70. King, T.D., M.J. Suto, and Y. Li, The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem, 2012. 113(1): p. 13-8. PMID:21898546
71. Kang, S.P., M. Martel, and L.N. Harris, Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol, 2008. 20(1): p. 40-6. PMID:18197004
72. Joensuu, H. and J. Gligorov, Adjuvant treatments for triple-negative breast cancers. Ann Oncol, 2012. 23 Suppl 6: p. vi40-5. PMID:23012301
73. Jaspers, J.E., S. Rottenberg, and J. Jonkers, Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta, 2009. 1796(2): p. 266-80. PMID:19616605
74. Ismail-Khan, R. and M.M. Bui, A review of triple-negative breast cancer. Cancer Control, 2010. 17(3): p. 173-6. PMID:20664514
75. Isakoff, S.J., Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J, 2010. 16(1): p. 53-61. PMID:20164691
76. Irvin, W.J., Jr. and L.A. Carey, What is triple-negative breast cancer? Eur J Cancer, 2008. 44(18): p. 2799-805. PMID:19008097
77. Hurvitz, S.A. and R.S. Finn, What's positive about 'triple-negative' breast cancer? Future Oncol, 2009. 5(7): p. 1015-25. PMID:19792970
78. Hudis, C.A. and L. Gianni, Triple-negative breast cancer: an unmet medical need. Oncologist, 2011. 16 Suppl 1: p. 1-11. PMID:21278435
79. Herold, C.I. and C.K. Anders, New targets for triple-negative breast cancer. Oncology (Williston Park), 2013. 27(9): p. 846-54. PMID:24282978
80. Hashimoto, K. and K. Tamura, [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]. Gan To Kagaku Ryoho, 2010. 37(7): p. 1187-91. PMID:20647696
81. Gucalp, A. and T.A. Traina, Triple-negative breast cancer: role of the androgen receptor. Cancer J, 2010. 16(1): p. 62-5. PMID:20164692
82. Guarneri, V., M.V. Dieci, and P. Conte, Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs, 2013. 73(12): p. 1257-65. PMID:23842749
83. Greenberg, S. and H.S. Rugo, Triple-negative breast cancer: role of antiangiogenic agents. Cancer J, 2010. 16(1): p. 33-8. PMID:20164688
84. Greenberg, S. and H.S. Rugo, Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer, 2010. 10 Suppl 2: p. S20-9. PMID:20805062
85. Goncalves, A., et al., [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. Bull Cancer, 2013. 100(5): p. 453-64. PMID:23695030
86. Gluz, O., et al., Triple-negative breast cancer--current status and future directions. Ann Oncol, 2009. 20(12): p. 1913-27. PMID:19901010
87. Gelmon, K., et al., Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol, 2012. 23(9): p. 2223-34. PMID:22517820
88. Ganesan, S., et al., Triple-negative breast cancers and the human mammary epithelial cell hierarchy. Breast Dis, 2010. 32(1-2): p. 49-61. PMID:22045329
89. Foulkes, W.D., I.E. Smith, and J.S. Reis-Filho, Triple-negative breast cancer. N Engl J Med, 2010. 363(20): p. 1938-48. PMID:21067385
90. Engebraaten, O., H.K. Vollan, and A.L. Borresen-Dale, Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol, 2013. 183(4): p. 1064-74. PMID:23920327
91. Elias, A.D., Triple-negative breast cancer: a short review. Am J Clin Oncol, 2010. 33(6): p. 637-45. PMID:20023571
92. Eiermann, W. and K.A. Vallis, Locoregional treatments for triple-negative breast cancer. Ann Oncol, 2012. 23 Suppl 6: p. vi30-4. PMID:23012299
93. Eiermann, W., et al., Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 2012. 21(1): p. 20-6. PMID:21983489
94. Duffy, M.J., P.M. McGowan, and J. Crown, Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer, 2012. 131(11): p. 2471-7. PMID:22581656
95. Dogan, B.E. and L.W. Turnbull, Imaging of triple-negative breast cancer. Ann Oncol, 2012. 23 Suppl 6: p. vi23-9. PMID:23012298
96. D'Ippolito, E. and M.V. Iorio, MicroRNAs and triple negative breast cancer. Int J Mol Sci, 2013. 14(11): p. 22202-20. PMID:24284394
97. Diaz-Cruz, E.S., et al., BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Dis, 2010. 32(1-2): p. 85-97. PMID:21778574
98. Diaz, L.K., et al., Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol, 2007. 14(6): p. 419-30. PMID:18049131
99. Dey, N., B.R. Smith, and B. Leyland-Jones, Targeting basal-like breast cancers. Curr Drug Targets, 2012. 13(12): p. 1510-24. PMID:22974394
100. de Ruijter, T.C., et al., Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol, 2011. 137(2): p. 183-92. PMID:21069385
101. De Laurentiis, M., et al., Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev, 2010. 36 Suppl 3: p. S80-6. PMID:21129616
102. Dawson, S.J., E. Provenzano, and C. Caldas, Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer, 2009. 45 Suppl 1: p. 27-40. PMID:19775602
103. Dawood, S., Triple-negative breast cancer: epidemiology and management options. Drugs, 2010. 70(17): p. 2247-58. PMID:21080741
104. Davis, S.L., et al., Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol, 2014. 6(3): p. 88-100. PMID:24790649
105. Crown, J., J. O'Shaughnessy, and G. Gullo, Emerging targeted therapies in triple-negative breast cancer. Ann Oncol, 2012. 23 Suppl 6: p. vi56-65. PMID:23012305
106. Criscitiello, C., et al., Understanding the biology of triple-negative breast cancer. Ann Oncol, 2012. 23 Suppl 6: p. vi13-8. PMID:23012296
107. Constantinidou, A., R.L. Jones, and J.S. Reis-Filho, Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther, 2010. 10(8): p. 1197-213. PMID:20735307
108. Comen, E.A. and M. Robson, Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J, 2010. 16(1): p. 48-52. PMID:20164690
109. Cleator, S., W. Heller, and R.C. Coombes, Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007. 8(3): p. 235-44. PMID:17329194
110. Clark, O., et al., Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid, 2014. 9: p. 1-11. PMID:24476748
111. Cirillo, D., et al., Leptin signaling in breast cancer: an overview. J Cell Biochem, 2008. 105(4): p. 956-64. PMID:18821585
112. Chen, J.Q. and J. Russo, ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta, 2009. 1796(2): p. 162-75. PMID:19527773
113. Chavez, K.J., S.V. Garimella, and S. Lipkowitz, Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis, 2010. 32(1-2): p. 35-48. PMID:21778573
114. Chacon, R.D. and M.V. Costanzo, Triple-negative breast cancer. Breast Cancer Res, 2010. 12 Suppl 2: p. S3. PMID:21050424
115. Carotenuto, P., et al., Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr, 2010. 20(1): p. 17-34. PMID:20528735
116. Carey, L., et al., Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol, 2010. 7(12): p. 683-92. PMID:20877296
117. Cadoo, K.A., M.N. Fornier, and P.G. Morris, Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging, 2013. 57(4): p. 312-21. PMID:24322788
118. Burstein, H.J., Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast, 2013. 22 Suppl 2: p. S147-8. PMID:24074776
119. Burness, M.L., T.A. Grushko, and O.I. Olopade, Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J, 2010. 16(1): p. 23-32. PMID:20164687
120. Brunello, A., et al., Targeted approaches to triple-negative breast cancer: current practice and future directions. Curr Med Chem, 2013. 20(5): p. 605-12. PMID:23278396
121. Bramati, A., et al., Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev, 2014. 40(5): p. 605-13. PMID:24529896
122. Brady-West, D.C. and D.A. McGrowder, Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 2011. 12(8): p. 2139-43. PMID:22292666
123. Boyle, P., Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 2012. 23 Suppl 6: p. vi7-12. PMID:23012306
124. Bouchalova, K., et al., Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2009. 153(1): p. 13-7. PMID:19365520
125. Bosch, A., et al., Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev, 2010. 36(3): p. 206-15. PMID:20060649
126. Berrada, N., S. Delaloge, and F. Andre, Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol, 2010. 21 Suppl 7: p. vii30-5. PMID:20943632
127. Bayraktar, S. and S. Gluck, Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat, 2013. 138(1): p. 21-35. PMID:23358903
128. Bartsch, R., et al., Triple-negative breast cancer. Wien Med Wochenschr, 2010. 160(7-8): p. 174-81. PMID:20473728
129. Badve, S., et al., Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol, 2011. 24(2): p. 157-67. PMID:21076464
130. Arslan, C., O. Dizdar, and K. Altundag, Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother, 2009. 10(13): p. 2081-93. PMID:19640211
131. Andre, F. and C.C. Zielinski, Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol, 2012. 23 Suppl 6: p. vi46-51. PMID:23012302
132. Anders, C.K., T.M. Zagar, and L.A. Carey, The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am, 2013. 27(4): p. 737-49, viii. PMID:23915742
133. Anders, C.K., et al., Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res, 2010. 16(19): p. 4702-10. PMID:20858840
134. Anders, C.K. and L.A. Carey, Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer, 2009. 9 Suppl 2: p. S73-81. PMID:19596646
135. Anders, C. and L.A. Carey, Understanding and treating triple-negative breast cancer. Oncology (Williston Park), 2008. 22(11): p. 1233-9; discussion 1239-40, 1243. PMID:18980022
136. Alluri, P. and L.A. Newman, Basal-Like and Triple-Negative Breast Cancers: Searching for Positives Among Many Negatives. Surg Oncol Clin N Am, 2014. 23(3): p. 567-577. PMID:24882351
137. Aapro, M. and H. Wildiers, Triple-negative breast cancer in the older population. Ann Oncol, 2012. 23 Suppl 6: p. vi52-5. PMID:23012304